Megan M Sheehan1, Anita J Reddy2, Michael B Rothberg3. 1. Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA. 2. Respiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA. 3. Center for Value-Based Care Research, Cleveland Clinic, Cleveland, Ohio, USA.
Abstract
BACKGROUND: Protection afforded from prior disease among patients with coronavirus disease 2019 (COVID-19) infection is unknown. If infection provides substantial long-lasting immunity, it may be appropriate to reconsider vaccination distribution. METHODS: This retrospective cohort study of 1 health system included 150 325 patients tested for COVID-19 infection via polymerase chain reaction from 12 March 2020 to 30 August 2020. Testing performed up to 24 February 2021 in these patients was included. The main outcome was reinfection, defined as infection ≥90 days after initial testing. Secondary outcomes were symptomatic infection and protection of prior infection against reinfection. RESULTS: Of 150 325 patients, 8845 (5.9%) tested positive and 141 480 (94.1%) tested negative before 30 August. A total of 1278 (14.4%) positive patients were retested after 90 days, and 62 had possible reinfection. Of those, 31 (50%) were symptomatic. Of those with initial negative testing, 5449 (3.9%) were subsequently positive and 3191 of those (58.5%) were symptomatic. Protection offered from prior infection was 81.8% (95% confidence interval [CI], 76.6-85.8) and against symptomatic infection was 84.5% (95% CI, 77.9-89.1). This protection increased over time. CONCLUSIONS: Prior infection in patients with COVID-19 was highly protective against reinfection and symptomatic disease. This protection increased over time, suggesting that viral shedding or ongoing immune response may persist beyond 90 days and may not represent true reinfection. As vaccine supply is limited, patients with known history of COVID-19 could delay early vaccination to allow for the most vulnerable to access the vaccine and slow transmission.
BACKGROUND: Protection afforded from prior disease among patients with coronavirus disease 2019 (COVID-19) infection is unknown. If infection provides substantial long-lasting immunity, it may be appropriate to reconsider vaccination distribution. METHODS: This retrospective cohort study of 1 health system included 150 325 patients tested for COVID-19 infection via polymerase chain reaction from 12 March 2020 to 30 August 2020. Testing performed up to 24 February 2021 in these patients was included. The main outcome was reinfection, defined as infection ≥90 days after initial testing. Secondary outcomes were symptomatic infection and protection of prior infection against reinfection. RESULTS: Of 150 325 patients, 8845 (5.9%) tested positive and 141 480 (94.1%) tested negative before 30 August. A total of 1278 (14.4%) positive patients were retested after 90 days, and 62 had possible reinfection. Of those, 31 (50%) were symptomatic. Of those with initial negative testing, 5449 (3.9%) were subsequently positive and 3191 of those (58.5%) were symptomatic. Protection offered from prior infection was 81.8% (95% confidence interval [CI], 76.6-85.8) and against symptomatic infection was 84.5% (95% CI, 77.9-89.1). This protection increased over time. CONCLUSIONS: Prior infection in patients with COVID-19 was highly protective against reinfection and symptomatic disease. This protection increased over time, suggesting that viral shedding or ongoing immune response may persist beyond 90 days and may not represent true reinfection. As vaccine supply is limited, patients with known history of COVID-19 could delay early vaccination to allow for the most vulnerable to access the vaccine and slow transmission.
Authors: Viviana Simon; Vamsi Kota; Ryan F Bloomquist; Hannah B Hanley; David Forgacs; Savita Pahwa; Suresh Pallikkuth; Loren G Miller; Joanna Schaenman; Michael R Yeaman; David Manthei; Joshua Wolf; Aditya H Gaur; Jeremie H Estepp; Komal Srivastava; Juan Manuel Carreño; Frans Cuevas; Ali H Ellebedy; Aubree Gordon; Riccardo Valdez; Sarah Cobey; Elaine F Reed; Ravindra Kolhe; Paul G Thomas; Stacey Schultz-Cherry; Ted M Ross; Florian Krammer Journal: mSphere Date: 2022-05-19 Impact factor: 5.029
Authors: Bram Decru; Jan Van Elslande; Sophie Steels; Gijs Van Pottelbergh; Lode Godderis; Bram Van Holm; Xavier Bossuyt; Johan Van Weyenbergh; Piet Maes; Pieter Vermeersch Journal: Front Immunol Date: 2022-06-15 Impact factor: 8.786
Authors: Sarah Wallace; Victoria Hall; Andre Charlett; Peter D Kirwan; Michele Cole; Natalie Gillson; Ana Atti; Jean Timeyin; Sarah Foulkes; Andrew Taylor-Kerr; Nick Andrews; Madhumita Shrotri; Sakib Rokadiya; Blanche Oguti; Amoolya Vusirikala; Jasmin Islam; Maria Zambon; Tim J G Brooks; Mary Ramsay; Colin S Brown; Meera Chand; Susan Hopkins Journal: BMJ Open Date: 2022-06-28 Impact factor: 3.006
Authors: Tawanda Chivese; Joshua T Matizanadzo; Omran A H Musa; George Hindy; Luis Furuya-Kanamori; Nazmul Islam; Rafal Al-Shebly; Rana Shalaby; Mohammad Habibullah; Talal A Al-Marwani; Rizeq F Hourani; Ahmed D Nawaz; Mohammad Z Haider; Mohamed M Emara; Farhan Cyprian; Suhail A R Doi Journal: Pathog Glob Health Date: 2022-01-31 Impact factor: 3.735
Authors: Laith J Abu-Raddad; Hiam Chemaitelly; Peter Coyle; Joel A Malek; Ayeda A Ahmed; Yasmin A Mohamoud; Shameem Younuskunju; Houssein H Ayoub; Zaina Al Kanaani; Einas Al Kuwari; Adeel A Butt; Andrew Jeremijenko; Anvar Hassan Kaleeckal; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Hanan F Abdul Rahim; Gheyath K Nasrallah; Hadi M Yassine; Mohamed Ghaith Al Kuwari; Hamad Eid Al Romaihi; Mohamed H Al-Thani; Abdullatif Al Khal; Roberto Bertollini Journal: EClinicalMedicine Date: 2021-04-28
Authors: Eamon O Murchu; Paula Byrne; Paul G Carty; Cillian De Gascun; Mary Keogan; Michelle O'Neill; Patricia Harrington; Máirín Ryan Journal: Rev Med Virol Date: 2021-05-27 Impact factor: 11.043